Hearing loss is a common sensory impairment in which hearing sensitivity is reduced to varying degrees from mild to profound. It may be unilateral or bilateral and can arise from congenital, infectious, environmental, pharmacologic, or age-related causes. Early detection and rehabilitation are important to reduce communication and developmental consequences.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
The FDA has denied or discouraged at least eight drug applications in the past year, including treatments for rare diseases, raising concerns about regulatory consistency and the future of experimental therapies.
Spruce Biosciences completed two Type B meetings with the FDA regarding tralesinidase alfa enzyme replacement therapy for Sanfilippo syndrome type B. The company now anticipates BLA submission in Q4 2026 to accommodate drug product process performance qualification requirements.
Researchers have identified a specific neurobiological link between age-related hearing loss and cognitive decline through a new biomarker called the Functional-Structural Ratio, which could help doctors predict dementia risk from brain scans.
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and two additional collaborations totaling over $1 billion to develop treatments for immune disorders, cancer, and hearing loss gene therapies.
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07582198 |
Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients |
NOT_YET_RECRUITING | NA |
| NCT07543770 |
Wind Noise Sound Quality Preference and Claims Study |
NOT_YET_RECRUITING | NA |
| NCT07526428 |
Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment |
ENROLLING_BY_INVITATION | NA |
| NCT07506408 |
Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Generalised Speech, Cognitive, and Communication Outcomes |
RECRUITING | NA |
| NCT07501312 |
Remote Microphone Performance Comparison in Adults With Hearing Loss |
ENROLLING_BY_INVITATION | NA |
| NCT07414329 |
Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit |
RECRUITING | NA |
| NCT07388784 |
Exploration of the Functional Effect of Modified Gain Precalculation on Soft Speech Intelligibility |
RECRUITING | NA |
| NCT07380269 |
Cochlear Implant Recipients: Comprehensive Longitudinal Evaluation |
RECRUITING | |
| NCT07338864 |
A Study to Evaluate Clinical Benefit, Performance and Safety of Cochlear Implants in Adults |
NOT_YET_RECRUITING | |
| NCT07304024 |
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound |
RECRUITING | PHASE1/PHASE2 |
